<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">

IP Regulation Front Cover


Section Partner:

Marks & Clerk logo - stacked

In Focus: IP, Regulation and Compliance

LSX C-Suite Challenges in Life Sciences Survey 2018

In this extract from the LSX C-Suite Challenges in Life Sciences Survey 2018, we focus on senior executive respondents’ perceptions of IP, compliance and regulatory issues. This includes their concerns about the impact of Brexit on the sector, the importance they place on IP protection, and the extent to which data protection features on senior leaders’ agendas. The LSX C-Suite Challenges in Life Sciences Survey 2018 has been designed to benchmark and give voice to the hurdles faced by C-level executives through key stages in the product and company development process.

Download the white paper to:
  • Gauge the temperature of respondents’ attitudes towards Brexit and its implications for the life sciences industry.
  • Find out what consequences of potential data breaches most worry respondents.
  • Gain insight into the role IP plays in each stage of a company’s development from Will Arends, Partner at Marks & Clerk.
  • Learn about the key areas of Brexit-related uncertainty for life sciences companies, as outlined by Dr Michael Hopkins, Senior Lecturer (SPRU - Science Policy Research Unit) at the University of Sussex Business School.

The IP, Regulation and Compliance report section and white paper are kindly supported by intellectual property firm Marks & Clerk.

Enter your details here to receive the report

Formerly Known as Blog Resize

LSX (formerly Biotech and Money) is an influential community of senior life science decision makers. Through our impactful events, powerful thought leadership content and unique networking opportunities, we exist to forge a fundamentally better way to promote and facilitate investment, financing, partnerships and deal making in healthcare.